(Q47421812)

16 January 2018

title

Is laboratory monitoring of low-molecular-weight heparin therapy necessary? No. (English)

1 reference

16 January 2018

1 reference

Bounameaux H

1

1 reference

16 January 2018

de Moerloose P

series ordinal

2

1 reference

16 January 2018

publication date

1 April 2004

1 reference

16 January 2018

Journal of Thrombosis and Haemostasis

published in

1 reference

16 January 2018

volume

2

1 reference

16 January 2018

issue

4

1 reference

16 January 2018

page(s)

551-554

1 reference

16 January 2018

Suboptimal Monitoring and Dosing of Unfractionated Heparin in Comparative Studies with Low-Molecular-Weight Heparin

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7933.2004.00648.X

Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7933.2004.00648.X

Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7933.2004.00648.X

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7933.2004.00648.X

Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7933.2004.00648.X

A longitudinal study of maternal dose response to low molecular weight heparin in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7933.2004.00648.X

An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7933.2004.00648.X

Is impaired renal function a contraindication to the use of low-molecular-weight heparin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7933.2004.00648.X

10.1111/J.1538-7933.2004.00648.X

21 January 2018

Identifiers

DOI

1 reference

16 January 2018

1 reference

16 January 2018